Respiratory Infections

The FDA has approved Lannet Company’s Abbreviated New Drug Application for levofloxacin oral solution USP, 25 mg/mL.

Although the incidence of nontuberculous mycobacterial (NTM) lung disease is increasing, and current treatment options are limited, certain NTM patients may find a potential treatment option in video-assisted thoracoscopic surgery.

The results of 2 studies indicate that patients who are overweight or obese have better mortality outcomes than patients who are at a normal weight when it comes to fighting off infectious diseases.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

With optimal distribution, even low-efficacy flu vaccines can make a difference, although their benefits vary somewhat depending on which age group has a high uptake rate.

New research suggests that too many patients with acute infections are dying in one South African city affected by high rates of HIV and TB.

The virus associated with the Middle East may or may not pose a threat to the United States, but researchers here are still working hard to find treatments and preventative vaccines.

Nabriva Therapeutics plans to file a New Drug Application with the FDA in the fourth quarter of 2018.

Procalcitonin levels can help differentiate bacterial and viral infections but did not influence antibiotic prescribing in hospital emergency departments.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Researchers from the Centers for Disease Control and Prevention call for better surveillance of enteroviruses and parechoviruses following outbreaks of respiratory illness and hand, foot, and mouth disease.

In case you missed them, we've compiled the top 5 articles from this past week.

A new report by Global Health Technologies Coalition assesses the economic impact of cuts to global health R&D on the economies of US states.

A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.

A recent study finds that ibrutinib may be associated with serious infections in patients with lymphoid cancer.

Specialists discuss causes and frontline prevention strategies in the infectious disease space.

Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.

Tuberculosis treatment is long and rigorous, but a new study by Johns Hopkins School of Medicine suggests that a smartphone application may help patients adhere to their daily medication regimens.

A recent survey explores prevention practices for Legionnaires’ disease and water management programs in health care facilities.

New agents are in development, but none represent a magic bullet for the problems that CRE infections present.

Many patients with pneumonia are empirically treated with anti-MRSA therapy, leaving antimicrobial stewardship programs faced with the challenge of identifying patients who truly warrant continuation of this therapy.

Representatives from Novavax, Inc., an American-based biotechnology company, presented data at the recent World Vaccine Congress in Washington, DC, on their vaccines under development for the flu and RSV.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Paratek’s omadacycline moves another step toward approval.

Investigators set out to find out why pertussis rates in the United States have been rising steadily despite the availability of a vaccine.

Health officials around the United States are still recommending the flu shot for late-season protection against the second wave of flu caused by influenza B.

Marin H. Kollef, MD, discusses new therapies in development for the treatment of Pseudomonas infections.

In case you missed them, we've compiled the top 5 articles from this past week.

With influenza B making a late-season rise, health officials are warning that B viruses may cause a second wave of flu this season, while the FDA is backing some alternatives to egg-based flu vaccines.

Antibiotics are the mainstay treatment for CAP; however, the additive role of corticosteroids is continually being debated.